Maja Hinge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maja Hinge has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Hans-Christian Slotved
Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
1 shared publication Helene A.S. Ingels
Department of Microbiological Surveillance and Research Statens Serum Institut Copenhagen Denmark
1 shared publicationIngolf Mølle
Department of Hematology Aarhus University Hospital Aarhus C
1 shared publication
Latest Publications
Serologic response to a 23‐valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma
Patients with multiple myeloma are known to have an increased risk of infections withStreptococcus pneumoniaeand vaccination is recommended. We retrospectively investigated the response of a 23‐valent polysaccharide‐based pneumococcal vaccine in 60 patients with multiple myeloma administered prior to autologous stem cell transplantation (ASCT). Specific antibody titers were measured before and after vaccination. Disease stage was evaluated and associated to the response. We found that 33% of the patients responded to the vaccine. There was a statistic significant association between response to the vaccine and disease stage (p = 0.01). We conclude that vaccination againstS. pneumoniaeprior toASCTis reasonable at least in patients responding well to induction therapy, but still it is important to be aware that the response is frequently poor and the duration of it is unknown.
Serologic response to a 23‐valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma
Patients with multiple myeloma are known to have an increased risk of infections withStreptococcus pneumoniaeand vaccination is recommended. We retrospectively investigated the response of a 23‐valent polysaccharide‐based pneumococcal vaccine in 60 patients with multiple myeloma administered prior to autologous stem cell transplantation (ASCT). Specific antibody titers were measured before and after vaccination. Disease stage was evaluated and associated to the response. We found that 33% of the patients responded to the vaccine. There was a statistic significant association between response to the vaccine and disease stage (p = 0.01). We conclude that vaccination againstS. pneumoniaeprior toASCTis reasonable at least in patients responding well to induction therapy, but still it is important to be aware that the response is frequently poor and the duration of it is unknown.